Early life innate immune signatures of persistent food allergy - 06/09/18
Abstract |
Background |
Food allergy naturally resolves in a proportion of food-allergic children without intervention; however the underlying mechanisms governing the persistence or resolution of food allergy in childhood are not understood.
Objectives |
This study aimed to define the innate immune profiles associated with egg allergy at age 1 year, determine the phenotypic changes that occur with the development of natural tolerance in childhood, and explore the relationship between early life innate immune function and serum vitamin D.
Methods |
This study used longitudinally collected PBMC samples from a population-based cohort of challenge-confirmed egg-allergic infants with either persistent or transient egg allergy outcomes in childhood to phenotype and quantify the functional innate immune response associated with clinical phenotypes of egg allergy.
Results |
We show that infants with persistent egg allergy exhibit a unique innate immune signature, characterized by increased numbers of circulating monocytes and dendritic cells that produce more inflammatory cytokines both at baseline and following endotoxin exposure when compared with infants with transient egg allergy. Follow-up analysis revealed that this unique innate immune signature continues into childhood in those with persistent egg allergy and that increased serum vitamin D levels correlate with changes in innate immune profiles observed in children who developed natural tolerance to egg.
Conclusions |
Early life innate immune dysfunction may represent a key immunological driver and predictor of persistent food allergy in childhood. Serum vitamin D may play an immune-modulatory role in the development of natural tolerance.
Le texte complet de cet article est disponible en PDF.Key words : Food allergy, innate, monocytes, persistent, natural tolerance, endotoxin, cytokines, vitamin D, HealthNuts
Abbreviations used : CD, DC, FACS, OFC, SPT
Plan
The HealthNuts study is supported by funding from the National Health and Medical Research Council of Australia (NHMRC), the Ilhan Food Allergy Foundation, AnaphylaxiStop, the Charles and Sylvia Viertel Medical Research Foundation, and the Victorian Government's Operational Infrastructure Support Program. The immunological work is supported by funding to M.R.N. from the Murdoch Childrens Research Institute and the NHMRC Centre for Food and Allergy Research. |
|
Disclosure of potential conflict of interest: M. L. Tang receives fees or funding from advisory boards from Nestle and Danone Nutricia; consultancy fees from Deerfield, GLG, and Bayer; grants from the National Health and Medical Research Council (NHMRC) Australia and ProTA Therapeutics; speaker fees from Danone Nutricia and Nestle Health Sciences; royalties from Wilkinson Publishing; and fees for the development of educational presentation from MD Linx; has stock in ProTA Therapeutics; is an inventor on a patent owned by the Murdoch Children's Research Institute; and works with ProTA Therapeutics. S. L. Prescott receives fees or funding from advisory boards from Danone, Nestle, Swisse, and Bayer; consultancy fees from Bayer; and speaker fees from Abbott and Health World and royalties from UpToDate. D. J. Martino received a grant from the NHMRC. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 142 - N° 3
P. 857 - septembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?